Acer Therapeutics Equity 2024

Acer Therapeutics Aktienanalyse

What does Acer Therapeutics do?

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel drugs for rare and life-threatening diseases. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. The history of Acer Therapeutics began with an innovative strategy for rediscovering already approved drugs for new therapeutic applications. The company utilizes a "repurposing" technology, in which already approved drugs are reevaluated and further developed for the treatment of rare diseases. Acer Therapeutics' business model includes a combination of in-house research activities, strategic partnerships, and acquisitions. The company follows a portfolio strategy with a focus on rare diseases to develop a diversified pipeline of innovative medications. The various divisions of Acer Therapeutics focus on different therapeutic areas. Currently, the company is focused on the development of drugs for the treatment of rare anemia, severe lymphocytic leukemia, and narcolepsy. Acer Therapeutics' flagship product is EDSIVO, a medication for the treatment of arterial hypertension, a rare and life-threatening condition characterized by elevated blood pressure in the arteries. EDSIVO is currently approved in the United States and is under review in Europe. The company plans to further develop EDSIVO for the treatment of other rare diseases. Another important product of Acer Therapeutics is ACER-001, a medication for the treatment of the rare metabolic disorder urea cycle disorders. ACER-001 is an oral formulation of sodium phenylbutyrate and is intended to help patients regulate ammonia metabolism and alleviate symptoms. In recent years, Acer Therapeutics has also entered into several strategic partnerships and acquisitions to expand and strengthen its pipeline of rare diseases. In 2019, the company acquired biopharmaceutical specialist Celipheon, thereby expanding its portfolio to include drugs for the treatment of anemia and leukemia. Another important partner of Acer Therapeutics is Ultragenyx Pharmaceutical, a biopharmaceutical company specializing in the development of therapies for rare and ultra-rare diseases. The two companies have entered into a licensing agreement for ACER-001, in which Ultragenyx has exclusive rights for the commercialization of the medication in North America and Europe. Overall, Acer Therapeutics' business model and portfolio strategy have made it a key player in the rare disease sector. Through partnerships and acquisitions, it has expanded its pipeline and focused its research on various therapeutic areas. The company is currently in a growth phase and has the potential to bring more groundbreaking medications for rare diseases to the market in the future. Acer Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Acer Therapeutics's Equity

Acer Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Acer Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Acer Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Acer Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Acer Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Acer Therapeutics stock

What is the equity of Acer Therapeutics this year?

Acer Therapeutics has equity of -16.76 M USD this year.

What was the equity of Acer Therapeutics compared to the previous year?

The equity of Acer Therapeutics has increased/decreased by 872.45% increased compared to the previous year.

What impact does a high equity have on investors of Acer Therapeutics?

A high equity is advantageous for investors of Acer Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Acer Therapeutics?

A low equity can be a risk for investors of Acer Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Acer Therapeutics affect the company?

An increase in equity of Acer Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Acer Therapeutics affect the company?

A reduction in equity of Acer Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Acer Therapeutics?

Some factors that can affect the equity of Acer Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Acer Therapeutics so important for investors?

The equity of Acer Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Acer Therapeutics take to change the equity?

To change equity, Acer Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Acer Therapeutics pay?

Over the past 12 months, Acer Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acer Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acer Therapeutics?

The current dividend yield of Acer Therapeutics is .

When does Acer Therapeutics pay dividends?

Acer Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acer Therapeutics?

Acer Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acer Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acer Therapeutics located?

Acer Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acer Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acer Therapeutics from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Acer Therapeutics pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Acer Therapeutics in the year 2023?

In the year 2023, Acer Therapeutics distributed 0 USD as dividends.

In which currency does Acer Therapeutics pay out the dividend?

The dividends of Acer Therapeutics are distributed in USD.